Institut National De La Sante Et De La Recherche Medicale

Laboratoires Des Produits Ethiques Ethypharm

Laboratoires Des Prodiuts Ethiques Ethypharm

Philippe Menei

Jean-Pierre Benoit

Nathalie Faisant

Marie-Claire Venier

Claudia Montero-Menei

Valérie Tatard

A method of repairing tissue includes implanting into a patient a therapeutically effective amount of a pharmaceutical composition including microparticles including a biodegradable, biocompatible material having cells of interest or fragments thereof adhered to at least a portion of a surface; and at least one substance active on the cells or their environment upon implantation of the microparticles in a patient associated with the material wherein the substances is released in a controlled or extended manner.

Microparticles supporting cells and active substances

The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of at least 90 weeks, a therapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used preferably contain 5-fluorouracile of the tumor, by intratissular injection. The radiotherapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.

Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma

The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of least 90 weeks, a thereapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used prefereably contain 5-fluorouracile of the tumor, by intratissular injection. The radiothereapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.

Growing community of inventors

Avrille, France

Philippe Menei